Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome

Stem Cells

Volumn 34, Issue 2, 2016, Pages 357-366

  Von Dalowski, Felix ^a   Kramer, Michael ^a   Wermke, Martin ^a   Wehner, Rebekka ^b   Röllig, Christoph ^a   Alakel, Nael ^a   Stölzel, Friedrich ^a   Parmentier, Stefani ^c   Sockel, Katja ^a   Krech, Mathias ^a   Schmitz, Marc ^b,d,e,f   Platzbecker, Uwe ^a   Schetelig, Johannes ^a,d   Bornhäuser, Martin ^a,d,f   Von Bonin, Malte ^a,d,e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Rems Murr Klinik   (Germany)

^d Deutsches Konsortium Für Translationale Krebsforschung DKTK   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Graft versus host disease; Mesenchymal stromal cells; Steroid refractory

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL LYSATE; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STROMA CELL; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE; ALLOGRAFT; DISEASE FREE SURVIVAL; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ACUTE DISEASE; ADULT; AGED; ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84958237819     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2224     Document Type: Article

References (60)

1. Storb R, Gyurkocza B, Storer BE, et al., Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31: 1530-1538.
2. Riddell SR, Berger C, Murata M, et al., The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003; 17: 153-162.
3. Weiden PL, Sullivan KM, Flournoy N, et al., Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
4. Martin PJ, Schoch G, Fisher L, et al., A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990; 76: 1464-1472.
5. Martin PJ, Rizzo JD, Wingard JR, et al., First- and second-line systemic treatment of acute graft-versus-host disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150-1163.
6. Mielcarek M, Storer BE, Boeckh M, et al., Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113: 2888-2894.
7. Van Lint MT, Uderzo C, Locasciulli A, et al., Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-2293.
8. Bacigalupo A,. Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87-98.
9. Alousi AM, Weisdorf DJ, Logan BR, et al., Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511-517.
10. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al., Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661-2668.
11. Busca A, Locatelli F, Marmont F, et al., Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 45-52.
12. de Lavallade H, Mohty M, Faucher C, et al., Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2006; 91: 1438-1440.
13. Furlong T, Martin P, Flowers ME, et al., Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009; 44: 739-748.
14. Gomez-Almaguer D, Ruiz-Arguelles GJ, del CT-A, et al., Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 10-15.
15. Hoda D, Pidala J, Salgado-Vila N, et al., Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010; 45: 1347-1351.
16. Macmillan ML, Weisdorf DJ, Davies SM, et al., Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40-46.
17. Perfetti P, Carlier P, Strada P, et al., Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008; 42: 609-617.
18. Schub N, Gunther A, Schrauder A, et al., Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011; 46: 143-147.
19. Griffin MD, Elliman SJ, Cahill E, et al., Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? Stem Cells 2013; 31: 2033-2041.
20. LeBlanc K, Rasmusson I, Sundberg B, et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
21. Arima N, Nakamura F, Fukunaga A, et al., Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: A pilot study. Cytotherapy 2010; 12: 265-268.
22. Ball LM, Bernardo ME, Roelofs H, et al., Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013; 163: 501-509.
23. Forslow U, Blennow O, LeBlanc K, et al., Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2012; 89: 220-227.
24. Herrmann R, Sturm M, Shaw K, et al., Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: A phase 1 study. Int J Hematol 2012; 95: 182-188.
25. Introna M, Lucchini G, Dander E, et al., Treatment of graft versus host disease with mesenchymal stromal cells: A phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014; 20: 375-381.
26. Jitschin R, Mougiakakos D, von Bahr L, et al., Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells 2013; 31: 1715-1725.
27. LeBlanc K, Frassoni F, Ball L, et al., Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586.
28. Lucchini G, Introna M, Dander E, et al., Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010; 16: 1293-1301.
29. Lucchini G, Dander E, Pavan F, et al., Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. Stem Cells Int 2012; 2012: 690236.
30. Perez-Simon JA, Lopez-Villar O, Andreu EJ, et al., Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: Results of a phase I/II clinical trial. Haematologica 2011; 96: 1072-1076.
31. Prasad VK, Lucas KG, Kleiner GI, et al., Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011; 17: 534-541.
32. Resnick IB, Barkats C, Shapira MY, et al., Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013; 3: 225-238.
33. Sanchez-Guijo F, Caballero-Velazquez T, Lopez-Villar O, et al., Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 1580-1585.
34. von Bahr L, Sundberg B, Lonnies L, et al., Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012; 18: 557-564.
35. von Bonin M, Stolzel F, Goedecke A, et al., Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43: 245-251.
36. Zhao K, Lou R, Huang F, et al., Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21: 97-104.
37. Martin PJ, Uberti JP, Soiffer RJ, et al., Prochymal improves response rates in patients with steroid-refractory acute graft versus disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010; 16: S169-170.
38. Bacigalupo A, Ballen K, Rizzo D, et al., Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
39. Rowlings PA, Przepiorka D, Klein JP, et al., IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864.
40. Martin PJ, Bachier CR, Klingemann HG, et al., Endpoints for clinical trials testing treatment of acute graft-versus-host disease: A joint statement. Biol Blood Marrow Transplant 2009; 15: 777-784.
41. Goedecke A, Wobus M, Krech M, et al., Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro. J Tissue Eng Regen Med 2011; 5: 648-654.
42. Dominici M, LeBlanc K, Mueller I, et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
43. Martin PJ, Schoch G, Fisher L, et al., A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 1991; 77: 1821-1828.
44. Deeg HJ,. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126.
45. Cuzzola M, Fiasche M, Iacopino P, et al., A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease. Haematologica 2012; 97: 1532-1538.
46. Ferrara JL, Harris AC, Greenson JK, et al., Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011; 118: 6702-6708.
47. Harris AC, Ferrara JL, Braun TM, et al., Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012; 119: 2960-2963.
48. Paczesny S, Krijanovski OI, Braun TM, et al., A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273-278.
49. Paczesny S, Braun TM, Levine JE, et al., Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010; 2: 13ra2.
50. Sakata N, Yasui M, Okamura T, et al., Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: The ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001; 27: 1153-1161.
51. Vander Lugt MT, Braun TM, Hanash S, et al., ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369: 529-539.
52. Ringden O, Uzunel M, Rasmusson I, et al., Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397.
53. Wang Y, Chen X, Cao W, et al., Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat Immunol 2014; 15: 1009-1016.
54. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
55. Lv FJ, Tuan RS, Cheung KM, et al., Concise review: The surface markers and identity of human mesenchymal stem cells. Stem Cells 2014; 32: 1408-1419.
56. Stagg J, Galipeau J,. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med 2013; 13: 856-867.
57. Horowitz MM, Gale RP, Sondel PM, et al., Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
58. Ning H, Yang F, Jiang M, et al., The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia 2008; 22: 593-599.
59. LeBlanc K, Tammik C, Rosendahl K, et al., HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
60. Schrepfer S, Deuse T, Reichenspurner H, et al., Stem cell transplantation: The lung barrier. Transplant Proc 2007; 39: 573-576.